PermRock Royalty Trust Declares Monthly Cash DistributionPRNewsWire · 4 days ago
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast CancerGlobeNewsWire · Oct 13, 2026
PermRock Royalty Trust (NYSE:PRT) Shares Down 1.1% – Here’s WhyDefense World · Oct 11, 2026
PermRock Royalty Trust (PRT) To Go Ex-Dividend on September 30thDefense World · Sep 28, 2026
PermRock Royalty Trust Declares Monthly Cash DistributionPRNewsWire · Sep 18, 2026
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective DegraderGlobeNewsWire · Sep 10, 2026PermRock Royalty Trust's primary asset is an 80% net profits interest derived from oil and natural gas production properties located within the Permian Basin of Texas. These energy-producing assets were originally acquired by Boaz Energy II, LLC. The total subsurface area encompassed by these holdings amounts to 22,997 net acres.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | $0.09 | $0.03 | Miss |
| May 14, 2026 | $0.09 | $0.03 | Miss |
| Mar 27, 2026 | $0.41 | $0.08 | Miss |
| Nov 13, 2025 | – | $0.09 | |
| Aug 13, 2025 | – | $0.10 | |
| May 14, 2025 | – | $0.12 |